title: Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
abstract: Teriflunomide, a once-daily, oral disease-modifying therapy, is a valuable new treatment option for the management of patients with relapsing-remitting multiple sclerosis. This article reviews key efficacy and safety data arising from pivotal teriflunomide studies that demonstrate the utility in treating both treatment-naïve patients and those previously treated with another disease-modifying therapy who, for a variety of reasons, may require an alternative treatment.
authors.affiliation: Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Aaron E
authors.initials: AE
authors.lastname: Miller
mesh_terms: D003437:Crotonates / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006885:Hydroxybutyrates; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009570:Nitriles; D012008:Recurrence; D014052:Toluidines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003437:Crotonates; D006885:Hydroxybutyrates; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide
keywords: clinical trials; disability; multiple sclerosis; progression; relapsing–remitting; teriflunomide